Immunotherapy innovation is saving the lives of cancer patients across the country, while researchers continue to break new ground in this growing oncology field. When Sameek Roychowdhury, MD, PhD, ...
StockStory.org on MSN
Spotting Winners: Natera (NASDAQ:NTRA) And Immuno-Oncology Stocks In Q3
The end of an earnings season can be a great time to discover new stocks and assess how companies are handling the current ...
AstraZeneca is extending its work with Immunai through a multiyear collaboration that aims to implement its artificial-intelligence-powered immune cell atlas in the design of the drugmaker’s clinical ...
StockStory.org on MSN
Q3 Earnings Highs And Lows: Exact Sciences (NASDAQ:EXAS) Vs The Rest Of The Immuno-Oncology Stocks
As the Q3 earnings season wraps, let’s dig into this quarter’s best and worst performers in the immuno-oncology industry, ...
Immuno-oncology has captured the attention of researchers and pharmaceutical industries worldwide. This promising treatment at the forefront of cancer research is already reaching patients and uses ...
When asked what Moleculent’s cell-cell interaction mapping technology provides to translational researchers, CEO Olle Ericsson explained that it adds “a new layer of information,” specifically ...
Takeda is offering Kumquat Biosciences the chance to make more than $1.2 billion biobucks in a new exclusive pact that centers around an unnamed immuno-oncology small-molecule inhibitor. Kumquat, ...
Lunit and Labcorp recently announced a collaboration to advance innovation in digital pathology and artificial intelligence for oncology research, leveraging Labcorp's clinical and pathology expertise ...
Click to open image viewer. CC0 Usage Conditions ApplyClick for more information. IIIF provides researchers rich metadata and media viewing options for comparison of works across cultural heritage ...
(RTTNews) - AIM ImmunoTech Inc. (AIM) said that it has signed a contract to sponsor a Phase 2a Human Challenge Trial to test the company's drug Ampligen as a potential intranasal antiviral therapy ...
Looking back on immuno-oncology stocks’ Q3 earnings, we examine this quarter’s best and worst performers, including Regeneron (NASDAQ:REGN) and its peers. Over the next few years, immuno-oncology ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback